Epigenetic
changes in cancer treatment

A new frontier of precision targeting in lethal cancers

EP31670
CLINICAL
EP31670
CLINICAL

EP31670 (= NEO2734)

A first-in-class oral once daily drug at the clinical testing stage

Guided by a very wide range of preclinical studies, this drug was selected among many other drug candidates to potently inhibit three different validated cancer drug targets: BET (BRD4) + p300/CBP + CECR2. Treatment is believed to result in both halted tumor growth as well as halted metastasis formation. This powerful drug fights cancer in multiple ways: (1) by eradicating tumor cells directly (cytotoxic therapy), (2) by unleashing the body’s immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy).

Read more
Read more

Clinical

Primary indications where all are backed by unprecedented preclinical data.

  • Metastatic castrate resistant prostate cancer (mCRPC)

  • NUT midline carcinoma (NC)

  • Pancreatic cancer (PDAC)

  • Breast cancer (TNBC and ER+)

Read more

IND 158612

IND in January 2022: ” study may proceed”